At a top level, Q2 revenue was $789.6 million, growing 6% as reported. During the quarter, we also deployed $136 million to repurchase 1.6 million shares. Looking back, since 2022, Globus has more than tripled our top line and earnings while developing a scalable working model to deliver these results over the long term. Our focus on organic growth, combined with the scale from the NuVasive merger and the Nevro acquisition, underscores our commitment to delivering value creation for our shareholders.
Our team has launched over 25 products over the past 36 months, demonstrating our unwavering focus on organic product development. The acquisition of Nevro, with a clinically superior pain product, opens the door for us expanding our addressable market into many exciting areas while bringing that franchise into our business model. Competitive recruiting, pull-through from robotics, and product launches continue to fuel growth. Strategically, competitive recruiting has and will remain at the forefront of our growth strategy.
spine, with double-digit growth seen in many products such as SABLE, ELSA, HEDRON C, Reline-C, and Reline Open. International spine grew 14% as reported and 12% on a constant currency basis, led by mid-teens growth across key EMEA markets, namely Italy, Spain, and Poland. APAC growth was broad-based across the region, while LATAM generated its growth mainly from Brazil and Colombia. The focus and infrastructure are such that we can position ourselves to see continued above-market growth moving ahead.